Keyword: Gritstone Oncology
Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
The deal sees Bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors.
Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
Dominic Caruso retires as J&J's CFO, CVS hires ex-Lilly CFO Rice as the president of its PBM unit, former FDA informatics chief Kass-Hout joins Amazon.
NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.
Our panel discussed the meaning of good science and how different players can work together to leverage their respective strengths.
After getting off a $102 million series A, Gritstone Oncology has followed up with an impressive $92.7 million second round.